STOCK MARKET BSE NSE

Favipiravir-Umifenovir trials start at Victoria Hospital

Soon, Victoria Hospital will start clinical trials using a combination of two antiviral drugs on Covid patients.

Published: 14th July 2020 03:13 AM  |   Last Updated: 14th July 2020 03:13 AM   |  A+A-

A doctor in a PPE suit comes out of Victoria Hospital on Tuesday | SHRIRAM B N

By Express News Service

BENGALURU: Soon, Victoria Hospital will start clinical trials using a combination of two antiviral drugs on Covid patients. Glenmark Pharmaceuticals, a global research-led company, is conducting Phase-3 of clinical trials to evaluate the efficacy of two antiviral drugs — Favipiravir and Umifenovir — as a combination therapy in moderate, hospitalised adult Covid patients in India. The study, called the ‘FAITH trial’, is looking to enrol 158 hospitalised patients.

In Bengaluru, Victoria Hospital will be leading the trials. A combined use of Favipiravir and Umifenovir offers a comprehensive antiviral cover on the pre-entry and post-entry life cycle of the SARS-CoV-2 virus. Both have shown efficacy in clinical trials. A spokesperson for Glenmark said, “Trials will start once investigations are done and after getting patients’ consent.” Dr Jayanthi CR, Director-Dean, BMCRI, said that they will be starting trials soon too. — Iffath Fathima 

Stay up to date on all the latest Bengaluru news with The New Indian Express App. Download now

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp